HK Stock Market Move | MGM China (02282) resumed trading in the afternoon and rose over 4%. Adjusted EBITDAR for the fourth quarter of last year increased by over 30% year-on-year.
MGM China (02282) resumes trading in the afternoon with a surge of over 4%, as of the time of writing, it has risen 3.87% to HK$13.42, with a turnover of HK$58.9956 million.
MGM CHINA (02282) resumed trading in the afternoon, rising more than 4%. As of the time of writing, it has increased by 3.87% to HK$13.42, with a turnover of HK$58.9956 million.
On the news front, MGM CHINA announced at noon that, according to preliminary unaudited financial information published by its major shareholder MGM Resorts International, for the year ended December 31, 2025, MGM CHINA achieved a net revenue of approximately US$4.462 billion, a year-on-year increase of 10.92%; Adjusted EBITDAR for the segment was US$1.203 billion, up 10.68% year-on-year. For the three months ended December 31, 2025, net revenues were approximately US$1.236 billion, an increase of 21.37% year-on-year; Adjusted EBITDAR for the segment was US$332 million, up 30.46% year-on-year.
Related Articles

HK Stock Market Move | XD INC (02400) rose nearly 5% in the late trading session. The company has launched an AI game creation intelligent body. The download volume of the international version of Heartbeat Town exceeded expectations.

A-share market closing review | Three major variables concentrated attacks! The Shanghai Composite Index fell by 0.64% on shrinking volume, with brokerage stocks supporting the market.

Biopharmaceutical company Eikon Therapeutics (EIKN.US) priced its IPO at $18, raising $381.2 million. It will debut on Nasdaq tonight.
HK Stock Market Move | XD INC (02400) rose nearly 5% in the late trading session. The company has launched an AI game creation intelligent body. The download volume of the international version of Heartbeat Town exceeded expectations.

A-share market closing review | Three major variables concentrated attacks! The Shanghai Composite Index fell by 0.64% on shrinking volume, with brokerage stocks supporting the market.

Biopharmaceutical company Eikon Therapeutics (EIKN.US) priced its IPO at $18, raising $381.2 million. It will debut on Nasdaq tonight.






